Head-To-Head Comparison: Organon & Co. (NYSE:OGN) vs. DocGo (NASDAQ:DCGO)

Organon & Co. (NYSE:OGN) and DocGo (NASDAQ:DCGO) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.

Earnings and Valuation

This table compares Organon & Co. and DocGo”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.40 billion	0.38	$864.00 million	$2.69	3.49
DocGo	$616.55 million	0.25	$19.99 million	($0.19)	-8.21

Organon & Co. has higher revenue and earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Organon & Co. has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, DocGo has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Organon & Co. and DocGo, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	1	2	2	1	2.50
DocGo	0	3	3	0	2.50

Organon & Co. presently has a consensus price target of $18.00, indicating a potential upside of 91.59%. DocGo has a consensus price target of $3.59, indicating a potential upside of 130.13%. Given DocGo’s higher possible upside, analysts plainly believe DocGo is more favorable than Organon & Co..

Profitability

This table compares Organon & Co. and DocGo’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Organon & Co.	11.15%	163.88%	6.99%
DocGo	-4.20%	-3.26%	-2.24%

Insider and Institutional Ownership

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 56.4% of DocGo shares are owned by institutional investors. 2.0% of Organon & Co. shares are owned by company insiders. Comparatively, 3.8% of DocGo shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Organon & Co. beats DocGo on 10 of the 14 factors compared between the two stocks.

About Organon & Co.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

About DocGo

DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.